Trials / Completed
CompletedNCT02095886
Relative Bioavailability Study With BMS-955176
Assessment of BMS-955176 Bioavailability From a Micronized Crystalline Tablet Relative to a Spray-Dried Dispersion Suspension and Assessment of Additional Experimental Formulations Relative to the Micronized Crystalline Tablet in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to select the best dose level (amount of drug given) and best formulation of the study drug (BMS-955176) to develop further.
Detailed description
Primary Purpose: Other: This study will assess the bioavailability of BMS-955176 from a micronized crystalline (MC) tablet relative to a spray-dried dispersion (SDD) suspension. Assessment of additional experimental formulations relative to the micronized crystalline tablet will also be performed
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-955176 | BMS-955176 |
Timeline
- Start date
- 2014-03-25
- Primary completion
- 2014-07-07
- Completion
- 2014-07-07
- First posted
- 2014-03-26
- Last updated
- 2017-09-11
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02095886. Inclusion in this directory is not an endorsement.